X
Xenon Pharmaceuticals Inc. (XENE)
NGM – Real Time Price. Currency in USD
54.48
-1.05 (-1.89%)
At close: Mar 27, 2026, 4:00 PM EDT
54.48
0.00 (0.00%)
After-hours: Mar 27, 2026, 4:34 PM EDT
Get all premium features to the best stock analysis tool
NGM – Real Time Price. Currency in USD
54.48
-1.05 (-1.89%)
At close: Mar 27, 2026, 4:00 PM EDT
54.48
0.00 (0.00%)
After-hours: Mar 27, 2026, 4:34 PM EDT
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company’s Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
| Name | Position |
|---|---|
| Dr. Christopher John Kenney M.D. | Chief Medical Officer |
| Dr. James R. Empfield Ph.D. | Executive Vice President of Drug Discovery |
| Dr. Matthew D. Ronsheim Ph.D. | Chief Operating Officer |
| Dr. Robin P. Sherrington Ph.D. | Executive Vice President of Strategy & Innovation |
| J.P. Gilbert | Senior Director |
| Mr. Darren S. Cline M.B.A. | Chief Commercial Officer and Member of Executive Team |
| Mr. Ian C. Mortimer C.M.A., CPA, M.B.A. | President, CEO, Principal Accounting Officer & Director |
| Mr. Thomas Patrick Kelly J.D. | Chief Financial Officer |
| Ms. Andrea DiFabio J.D. | Chief Legal Officer & Corporate Secretary |
| Ms. Shelley McClCoskey B.A. | Executive Vice President of Human Resources |
| Date | Type | Document |
|---|---|---|
| 2026-03-13 | 8-K | xene-20260313.htm |
| 2026-03-12 | 8-K | d97906d8k.htm |
| 2026-03-09 | 8-K | d107087d8k.htm |
| 2025-12-01 | 8-K | xene-20251124.htm |
| 2025-11-03 | 10-Q | xene-20250930.htm |
| 2025-10-17 | 8-K/A | xene-20251015.htm |
| 2025-10-16 | 8-K | xene-20251015.htm |
| 2025-08-11 | 8-K | xene-20250811.htm |
| 2025-07-03 | 8-K | xene-20250630.htm |
| 2025-06-05 | 8-K | xene-20250604.htm |